Total trials
164
Active
18
Phase 3
3
Total enrollment
68,166
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Capecitabine | — | — | — | — | — | 2 | |
| Baclofen | — | — | — | — | — | 1 |
Next readouts
- 2026-01
- 2026-10
Top conditions
- Critical Illness9
- Mechanical Ventilation Complication4
- COVID-193
- Colorectal Cancer3
- Surgery3
- Colon Cancer3
- Fatigue3
- Inflammatory Bowel Diseases3
Frequently asked questions about Corporacion Parc Tauli
- How many clinical trials does Corporacion Parc Tauli have on ClinicalTrials.gov?
- Corporacion Parc Tauli is listed as the lead sponsor on 164 clinical trials in ClinicalTrials.gov, 18 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Corporacion Parc Tauli's trials are in Phase 3?
- 3 of Corporacion Parc Tauli's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Corporacion Parc Tauli focus on?
- Corporacion Parc Tauli's most-studied conditions on ClinicalTrials.gov are Critical Illness, Mechanical Ventilation Complication, COVID-19, Colorectal Cancer, Surgery.
- When are Corporacion Parc Tauli's next clinical trial readouts?
- Corporacion Parc Tauli has 2 upcoming primary-completion readouts tracked here; the soonest is “Safety & Efficacy of Baclofen for Alcohol Withdrawal in Chronic Liver Disease With Active Alcohol Consumption”, expected around 2026-01.